Flunoxaprofen

Flunoxaprofen

Clinical data
ATC code	G02CC04 (WHO) M01AE15 (WHO)
Identifiers
IUPAC name (2S)-2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
CAS Number	66934-18-7^Y
PubChem CID	68869
ChemSpider	62101^N
UNII	UKU5U19W9M
KEGG	D07219^Y
ChEBI	CHEBI:76154^N
ChEMBL	ChEMBL1614641^N
CompTox Dashboard (EPA)	DTXSID00912311
Chemical and physical data
Formula	C16H12FNO3
Molar mass	285.274 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](c1ccc2c(c1)nc(o2)c3ccc(cc3)F)C(=O)O
InChI InChI=1S/C16H12FNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)/t9-/m0/s1^N Key:ARPYQKTVRGFPIS-VIFPVBQESA-N^N
^NY (what is this?)  (verify)

Flunoxaprofen, also known as Priaxim, is a chiral nonsteroidal anti-inflammatory drug (NSAID). It is closely related to naproxen, which is also an NSAID. Flunoxaprofen has been shown to significantly improve the symptoms of osteoarthritis and rheumatoid arthritis. The clinical use of flunoxaprofen has ceased due to concerns of potential hepatotoxicity.

Structure

Flunoxaprofen is a two-ring heterocyclic compound derived from benzoxazole. It also contains a fluorine atom and a propanoyl group.

Synthesis

The overall synthesis is similar to that for benoxaprofen; in this case, para-fluorobenzoyl chloride is used when forming the benzoxazole ring..

A Sandmeyer reaction by diazotisation of 2-(4-aminophenyl)propanenitrile (1) followed by acid hydrolysis leads to the phenol (2), which is nitrated and reduced using stannous chloride or catalytic hydrogenation to give the aminophenol (4). Hydrolysis of the nitrile produces the carboxylic acid (5), which is converted to racemic flunoxaprofen by acylation with p-fluorobenzoyl chloride, followed by cyclisation.^[1][2][3][4]

Preparations

Because flunoxaprofen has limited water-solubility, additional steps must be taken in order to prepare syrups, creams, suppositories, etc. In order to make flunoxaprofen water-soluble, yet still active and efficient, it must be mixed with lysine and then suspended in an organic solvent that is soluble in water. A salt will crystallize upon cooling. The salt must then be filtered out and dried. Pharmacological testing of this now water-soluble compound has shown that it has anti-inflammatory properties equal to flunoxaprofen by itself.^[5]

Pharmacokinetics

The efficacy and safety of flunoxaprofen has been compared with those of naproxen in rheumatoid arthritis patients to show that the two drugs have equivalent therapeutical effects. Both drugs significantly relieve spontaneous pain which occurs both during the day and at night. Both drugs also significantly relieve the pain associated with active and passive motion and aid in relieving morning stiffness. The study also showed both drugs to be equally effective at improving grip strength.^[6]

Flunoxaprofen is administered as racemate. The absorption and disposition of both enantiomers were studied in 1988. No significant differences between stereoisomers were detected with respect to their absorption and elimination half-lives.^[7] However, further studies have shown that the S-enantiomer is the pharmacologically active form of the drug and does not undergo stereoinversion, while R-Flunoxaprofen is pharmacologically activated through biotransformation to the S-enantiomer.^[8] This stereospecific chiral inversion is mediated by the FLX-S-Acyl-CoA thioester.^[9] Pharmacokinetic studies with stereoselective bioassays have been carried out in different species after racemate dosage (and flunoxaprofen enantiomer derivatives have also been used as chiral fluorescent derivatizing agents to determine the enantiomers of other drug enantiomers in plasma).^[10]

It has been shown that the dextrorotatory form is particularly active and has a much higher therapeutic index than some other anti-inflammatories, including indomethacin and diclofenac.^[5] It has also been shown that flunoxaprofen inhibits leukotriene rather than prostaglandin synthesis. This is similar to benoxaprofen. Flunoxaprofen and benoxaprofen have been shown to have similar absorption characteristics. However, the distribution and elimination of flunoxaprofen has been shown to be much faster than benoxaprofen.^[11]

Adverse effects

A structural analog of flunoxaprofen is benoxaprofen. The two drugs are carboxylic acid analogs that form reactive acyl glucuronides. Benoxaprofen has been shown to be involved in rare hepatotoxicity. Because of this, benoxaprofen has been removed from the market. In response to this the clinical use of flunoxaprofen has also stopped, even though studies have shown that flunoxaprofen is less toxic than benoxaprofen.

The toxicity of these nonsteroidal anti-inflammatory drugs may be related to the covalent modification of proteins in response to the drugs' reactive acyl glucuronides. The reactivity of the acyl glucuronides appears to co-determine the extent of protein binding,^[12] as initially proposed by the research group of Benet et al. in 1993.

References

1. DE 2324443, Evans, Delme; Dunwell, David William & Hicks, Terence Alan, "Benzoxazol-Derivate und Verfahren zu ihrer Herstellung [Benzoxazole Derivatives and processes for their production]", published 1973-11-29, assigned to Lilly Industries Ltd. 
2. D. Evans et al., U.S. patent 3,912,748 (1975 to Eli Lilly).
3. Dunwell DW, Evans D, Hicks TA (January 1975). "2-aryl-5-benzoxazolealkanoic acid derivatives with notable antiinflammatory activity". Journal of Medicinal Chemistry. 18 (1): 53–58. doi:10.1021/jm00235a012. PMID 1109576.
4. "Flunoxaprofen". Thieme. Retrieved 2024-07-09.
5. "Preparation process for making water-soluble lysine salts of (+)2-(4-fluorophenyl)-alpha-methyl-5-benzoxazole acetic acid" U.S. patent 5,120,851
6. Fioravanti A, Giordano N, Megale F, Jovane D, Franci A, Marcolongo R (1989). "[Efficacy and tolerability of flunoxaprofen in the treatment of rheumatoid arthritis. A cross-over clinical study using naproxen]". La Clinica Terapeutica (in Italian). 131 (2): 83–91. PMID 2533024.
7. Palatini P, Montanari G, Perosa A, Forgione A, Pedrazzini S, Furlanut M (1988). "Stereospecific disposition of flunoxaprofen enantiomers in human beings". International Journal of Clinical Pharmacology Research. 8 (3): 161–7. PMID 3403103.
8. Pedrazzini S, De Angelis M, Muciaccia WZ, Sacchi C, Forgione A (1988). "Stereochemical pharmacokinetics of the 2-arylpropionic acid non-steroidal antiinflammatory drug flunoxaprofen in rats and in man". Arzneimittel-Forschung. 38 (8): 1170–5. PMID 3196413.
9. Grillo MP, Wait JC, Tadano Lohr M, Khera S, Benet LZ (2010). "Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes". Drug Metabolism and Disposition. 38 (1): 133–42. doi:10.1124/dmd.109.029371. PMC 2802421. PMID 19786506.
10. Martin E, Quinke K, Spahn H, Mutschler E (1989). "(−)-(S)-flunoxaprofen and (−)-(S)-naproxen isocyanate: two new fluorescent chiral derivatizing agents for an enantiospecific determination of primary and secondary amines". Chirality. 1 (3): 223–34. doi:10.1002/chir.530010308. PMID 2642051.
11. Furlanut M, Montanari G, Perosa A, Velussi C, Forgione A, Palatini P (1985). "Absorption and disposition kinetics of flunoxaprofen and benoxaprofen in healthy volunteers". International Journal of Clinical Pharmacology Research. 5 (3): 165–70. PMID 4018949.
12. Dong JQ, Liu J, Smith PC (2005). "Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo". Biochemical Pharmacology. 70 (6): 937–48. doi:10.1016/j.bcp.2005.05.026. PMID 16046212.